File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration

TitleRed Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration
Authors
Keywordsage-related macular degeneration
dasatinib
dimeric prodrug
photodynamic therapy
red-light activation
Issue Date14-Sep-2023
PublisherWiley Open Access
Citation
Advanced Science, 2023, v. 10, n. 31 How to Cite?
Abstract

Choroidal neovascularization (CNV) is the key pathological event of wet age-related macular degeneration (wAMD) leading to irreversible vision loss. Currently, anti-angiogenic therapy with anti-vascular endothelial growth factor (VEGF) agents has become the standard treatment for wAMD, while it is still subject to several limitations, including the safety concerns of monthly intravitreal administration and insufficient efficacy for neovascular occlusion. Combined therapy with photodynamic therapy (PDT) and anti-angiogenic agents has emerged as a novel treatment paradigm. Herein, a novel and less-invasive approach is reported to achieve anti-angiogenic and photodynamic combination therapy of wAMD by intravenous administration of a photoactivatable nanosystem (Di-DAS-VER NPs). The nanosystem is self-assembled by reactive oxygen species (ROS)-sensitive dasatinib (DAS) prodrug and photosensitizer verteporfin (VER). After red-light irradiation to the diseased eyes, intraocular release of anti-angiogenic DAS is observed, together with selective neo-vessels occlusion by VER-generated ROS. Notably, Di-DAS-VER NPs demonstrates promising therapeutic efficacy against CNV with minimized systemic toxicity. The study enables an efficient intravenous wAMD therapy by integrating a photoactivation process with combinational therapeutics into one simple nanosystem.

A red-light-triggered intraocular drug release strategy is applied to achieve an anti-angiogenic and photodynamic combination treatment of wet age-related macular degeneration (wAMD) via intravenous administration of a photoactivatable nanosystem (Di-DAS-VER NPs). The nanosystem demonstrates strengthened choroidal neovascularization suppression and favorable biosafety profiles in vivo. This novel design has clinical potential for minimally-invasive delivery of combination therapeutics for treating angiogenic eye diseases.image


Persistent Identifierhttp://hdl.handle.net/10722/339307
ISSN
2023 Impact Factor: 14.3
2023 SCImago Journal Rankings: 3.914
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXu, Shuting-
dc.contributor.authorCui, Kaixuan-
dc.contributor.authorLong, Kaiqi-
dc.contributor.authorLi, Jia-
dc.contributor.authorFan, Ni-
dc.contributor.authorLam, Wai‐Ching-
dc.contributor.authorLiang, Xiaoling-
dc.contributor.authorWang, Weiping-
dc.date.accessioned2024-03-11T10:35:34Z-
dc.date.available2024-03-11T10:35:34Z-
dc.date.issued2023-09-14-
dc.identifier.citationAdvanced Science, 2023, v. 10, n. 31-
dc.identifier.issn2198-3844-
dc.identifier.urihttp://hdl.handle.net/10722/339307-
dc.description.abstract<p>Choroidal neovascularization (CNV) is the key pathological event of wet age-related macular degeneration (wAMD) leading to irreversible vision loss. Currently, anti-angiogenic therapy with anti-vascular endothelial growth factor (VEGF) agents has become the standard treatment for wAMD, while it is still subject to several limitations, including the safety concerns of monthly intravitreal administration and insufficient efficacy for neovascular occlusion. Combined therapy with photodynamic therapy (PDT) and anti-angiogenic agents has emerged as a novel treatment paradigm. Herein, a novel and less-invasive approach is reported to achieve anti-angiogenic and photodynamic combination therapy of wAMD by intravenous administration of a photoactivatable nanosystem (Di-DAS-VER NPs). The nanosystem is self-assembled by reactive oxygen species (ROS)-sensitive dasatinib (DAS) prodrug and photosensitizer verteporfin (VER). After red-light irradiation to the diseased eyes, intraocular release of anti-angiogenic DAS is observed, together with selective neo-vessels occlusion by VER-generated ROS. Notably, Di-DAS-VER NPs demonstrates promising therapeutic efficacy against CNV with minimized systemic toxicity. The study enables an efficient intravenous wAMD therapy by integrating a photoactivation process with combinational therapeutics into one simple nanosystem.</p><p>A red-light-triggered intraocular drug release strategy is applied to achieve an anti-angiogenic and photodynamic combination treatment of wet age-related macular degeneration (wAMD) via intravenous administration of a photoactivatable nanosystem (Di-DAS-VER NPs). The nanosystem demonstrates strengthened choroidal neovascularization suppression and favorable biosafety profiles in vivo. This novel design has clinical potential for minimally-invasive delivery of combination therapeutics for treating angiogenic eye diseases.image</p>-
dc.languageeng-
dc.publisherWiley Open Access-
dc.relation.ispartofAdvanced Science-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectage-related macular degeneration-
dc.subjectdasatinib-
dc.subjectdimeric prodrug-
dc.subjectphotodynamic therapy-
dc.subjectred-light activation-
dc.titleRed Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1002/advs.202301985-
dc.identifier.scopuseid_2-s2.0-85170691721-
dc.identifier.volume10-
dc.identifier.issue31-
dc.identifier.eissn2198-3844-
dc.identifier.isiWOS:001065306400001-
dc.identifier.issnl2198-3844-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats